News | Heart Failure | May 26, 2017

Arto System Shows Promise as Less-Invasive Therapy for Heart Failure Patients

Three-year and 30-day outcomes from global MAVERIC clinical trial demonstrate utility of the system to treat functional mitral valve regurgitation

Arto System Shows Promise as Less-Invasive Therapy for Heart Failure Patients

May 26, 2017 — Recent outcomes from the MAVERIC clinical trial confirm earlier positive findings that MVRx’s Arto System safely and effectively treats mitral valve regurgitation associated with congestive heart failure. The results, presented by leading cardiologists at EuroPCR 2017, May 16-19 in Paris, France, offer heart patients the promise of a less-invasive treatment for a life-threatening problem that affects more than 5 million people worldwide.

The ARTO System, a proprietary implantable device, is designed to improve heart failure symptoms by reducing mitral valve regurgitation, or the backward leakage of blood through the mitral valve, thereby increasing the forward flow of blood to the rest of the body. As a result, the heart functions more effectively and efficiently, leading to improved circulation, breathing and exercise tolerance.

The three-year Phase I portion of the MAVERIC study included 11 patients enrolled at Pauls Stradins University Clinical Hospital, Riga, Latvia. The results, presented by principal investigator Andrejs Erglis, M.D., Ph.D., demonstrate that the Arto System continues to provide a strong safety profile with 100 percent device success. Researchers found no instances of coronary artery compression, significantly reduced mitral valve regurgitation and significantly improved New York Heart Association (NYHA) heart function classification, a measure of heart failure. Moreover, heart-failure hospitalization fell 64 percent in the two years after Arto treatment compared with the two years prior. These results match those previously reported at earlier time points.

The current 30-day results from the multi-center MAVERIC trial were presented by Stephen Worthley, MB, BS, Ph.D., on behalf of the MAVERIC investigators. The report encompassed 45 patients inclusive of the 11 Phase I patients and represents a significant acceleration of enrollment beyond the single-center study. The 30-day results demonstrate that the Arto System is safe with 100 percent device success; there were no deaths, strokes or myocardial infarctions. At one month the findings also showed significantly reduced mitral valve regurgitation and significantly improved heart function. The 30-day results demonstrate that the safe and beneficial performance seen in the Phase I single-center study persists in a multi-center multi-operator setting.

For more information:

Related Content

Videos | Cath Lab| January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab| January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab| November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab| November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab| November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab| November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Three-Year Quality of Life Improvements Similar for PCI and CABG in Left Main Disease
News | Cath Lab| October 30, 2017
October 30, 2017 — New study results from the EXCEL trial comparing the quality of life (QoL) of patients with left m
Corindus Evaluates Incorporating HeartFlow Technology With CorPath GRX System
Technology | Cath Lab| October 26, 2017
Corindus Vascular Robotics Inc. announced that it will incorporate the HeartFlow FFRct (fractional flow reserve-...
Shockwave Medical Announces $35 Million in New Financing
News | Cath Lab| October 24, 2017
October 24, 2017 — Shockwave Medical reported $35 million in new financing, an extension of the company’s previously
Overlay Init